Latest Epilepsy News

Page 3 of 3

Percheron Therapeutics Cuts ATL1103, Limits ATL1102 Spend, Eyes New Rare Disease Assets

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Ada Torres

30 Apr 2025

Browse the archive

Full archive

Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026